Last updated: April 27, 2026
What is EP2529621, and what does it try to protect?
EP2529621 is a European patent application granted in the EP register for a drug-related invention. The document title, applicant, assignee chain, and exact claim set define the effective scope in force across EPC member states where it was validated.
Core scope for an EP drug patent in practice is determined by:
- Independent claims (the invention boundary)
- Dependent claims (fallback positions and claim “breadth”)
- Key term definitions inside the specification (drug substance, salts, polymorphs, formulations, dosages, use claims)
- Claim category (product, process, or therapeutic use) which sets enforceability posture in Europe
Result: A complete and accurate scope-and-claims analysis requires the exact claim text and legal status per jurisdiction (validated states, opposition history, limitation, or revocation). That information is not present in the prompt.
What are the exact claim elements and how do they define claim scope?
A defensible claims-scope map for EP drug patents requires the literal language of:
- Claim 1 (and any other independent claims)
- Defined terms for the drug substance or active ingredient
- Claim limitations for:
- chemical structure class or formula
- salt/polymorph/water content
- formulation components and concentration ranges
- dosage regimen (mg, frequency, duration)
- therapeutic indication (therapeutic use claims)
- patient population descriptors (if present)
Result: Without the published EP claim set text, any attempt to paraphrase or reconstruct scope risks factual error and is not suitable for high-stakes R&D or investment decisions.
How broad is EP2529621 in practice across the European market?
Market-relevant breadth in the EPO/EP enforcement context turns on:
- Whether the claims are composition/product claims or Swiss-type/use claims
- Whether the claim scope is limited to a single molecule or a generic genus
- Whether it covers only specific formulations/dosages
- Whether it covers specific salt forms or polymorphs
- Whether it includes process claims that can capture manufacturing workarounds
- Whether amendments during prosecution narrowed claim language
Result: Breadth grading (narrow/medium/broad) depends on the literal claim limitations, which are not provided.
What does the claim set imply for freedom-to-operate (FTO) in Europe?
European FTO risk from EP drug patents is typically driven by:
- Direct infringement risk if an authorized generic or parallel importer practices the claimed product/use
- Injunction leverage (more likely for composition/product claims and specific-use claims)
- Design-around feasibility:
- switching to a different salt form or polymorph
- using a different formulation vehicle
- changing dose frequency or regimen (if regimen limitations exist)
- switching indication (if indication-limited)
- Regulatory data exclusivity vs patent term: patents may survive past regulatory exclusivity cliffs
Result: FTO mapping requires knowing claim category and limitations and then aligning them with generic SmPC product features and label/regimen.
What is the EP2529621 patent landscape across Europe?
A complete landscape view for an EP drug patent includes:
- Validated states (country-by-country)
- Opposition status at EPO (opposed/not opposed, outcomes, amended claims)
- National court interpretations (if litigated)
- Family members (priority chain, corresponding PCT/US/JP/KR/other filings)
- Linkage to other patents (same product in Europe: formulation, crystal form, second medical use, manufacturing)
Result: These elements require access to:
- legal status and register data
- INPADOC family data
- EPO register outcome documents
None are available in the prompt.
What does this mean for other patents in the same drug family (typical clustering)?
In Europe, drug patent families usually cluster into:
- Substance/compound patents
- Salt/polymorph and solid form patents
- Formulation patents
- Second medical use patents
- Process/manufacturing patents
- Combination therapy patents
EP2529621’s placement within that cluster depends on claim category and subject matter (again, not provided).
What to extract from EP2529621 to build an investable claims map
For a complete, accurate analysis, the following exact items must be taken from the published EP specification:
Claim set (required)
- Claim 1 (independent): full text
- All independent claims
- Dependent claims that:
- narrow active ingredient definition
- specify salts/polymorphs
- specify formulations and dosage ranges
- specify therapeutic indications and dosing regimens
Definitions (required)
- Any definitions in the description that change scope (e.g., “pharmaceutically acceptable salt” definitions, preferred polymorphs, “effective amount” parameters)
Priority and legal status (required)
- Earliest priority date
- Publication date(s)
- Grant date
- Validated EPC states
- Opposition events and current claim set post-grant amendment if any
Landscape linkage (required)
- INPADOC family: corresponding jurisdictions
- Any related EPs in the same family that cover different aspects (second medical use, solid forms, combinations)
Result: Without those exact inputs, a claims map or landscape cannot be reliably produced.
Key Takeaways
- EP2529621’s enforceable claim scope is determined by its literal claim language, claim category, defined terms in the specification, and post-grant legal status across validated EPC states.
- A rigorous European patent landscape requires validated-state data, opposition outcomes, and family/linked patent relationships from EPO/INPADOC legal status sources.
- The prompt does not provide the claim text, legal status, validated jurisdictions, opposition history, or family data necessary for an accurate analysis.
FAQs
1) Does EP2529621 protect a compound, a formulation, or a therapeutic use?
It depends on the claim category and independent claim language in EP2529621. The prompt does not include that text, so a definitive determination cannot be made.
2) Is the scope limited to a specific salt or polymorph?
That is typically controlled by dependent claims and definitions in the specification. The claim set is not provided in the prompt.
3) Can a generic design around EP2529621 by changing dose regimen or excipients?
Only if the independent claims include regimen- or formulation-specific limitations. The prompt does not include claims, so this cannot be assessed.
4) Was EP2529621 opposed or limited by amendments at the EPO?
Opposition history materially changes enforceable claim scope. The prompt does not include EPO legal status data.
5) Which European countries face enforceable coverage under EP2529621?
Coverage depends on which states it was validated in. The prompt does not include validated-state information.
References
[1] European Patent Office. EP2529621 (publication and legal status records).
[2] EPO Global Dossier / INPADOC. EP2529621 family and legal events.
[3] Espacenet. EP2529621 bibliographic data and publications.
